## Travis E Grotz

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6105641/publications.pdf

Version: 2024-02-01

257357 360920 1,648 86 24 35 h-index citations g-index papers 86 86 86 2251 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Prognostic factors in Merkel cell carcinoma: Analysis of 240 cases. Journal of the American Academy of Dermatology, 2013, 68, 425-432.	0.6	155
2	Hepatic epithelioid haemangioendothelioma: is transplantation the only treatment option?. Hpb, 2010, 12, 546-553.	0.1	87
3	Early-onset gastric cancer is a distinct disease with worrisome trends and oncogenic features. Surgery, 2019, 166, 547-555.	1.0	72
4	Adult Intussusception in the Last 25ÂYears of Modern Imaging: Is Surgery Still Indicated?. Journal of Gastrointestinal Surgery, 2011, 15, 1699-1705.	0.9	61
5	Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis. Modern Pathology, 2011, 24, 487-494.	2.9	51
6	Sentinel lymph node biopsy in Merkel cell carcinoma: The Mayo Clinic experience of 150 patients. Surgical Oncology, 2018, 27, 11-17.	0.8	48
7	Negative Sentinel Lymph Node Biopsy in Merkel Cell Carcinoma is Associated with a Low Risk of Same-Nodal-Basin Recurrences. Annals of Surgical Oncology, 2015, 22, 4060-4066.	0.7	39
8	Safety and Feasibility of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma (SAFE-MILND). Annals of Surgery, 2017, 265, 192-196.	2.1	39
9	Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. American Journal of Surgery, 2020, 219, 478-483.	0.9	39
10	Minimally Invasive Inguinal Lymph Node Dissection (MILND) for Melanoma: Experience from Two Academic Centers. Annals of Surgical Oncology, 2013, 20, 340-345.	0.7	34
11	Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy. Surgery, 2020, 167, 803-811.	1.0	32
12	Concurrent MCL1 and JUN amplification in pseudomyxoma peritonei: a comprehensive genetic profiling and survival analysis. Journal of Human Genetics, 2014, 59, 124-128.	1.1	31
13	The effect of the AJCC 7th edition change in T1 melanoma substaging on national utilization and outcomes of sentinel lymph node biopsy for thin melanoma. Melanoma Research, 2015, 25, 157-163.	0.6	31
14	Surveillance strategies for gastrointestinal stromal tumors. Journal of Surgical Oncology, 2011, 104, 921-927.	0.8	30
15	Rare Presentations of Primary Melanoma and Special Populations. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 635-641.	0.6	30
16	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection. Annals of Surgical Oncology, 2017, 24, 2646-2654.	0.7	30
17	Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer. Annals of Surgical Oncology, 2022, 29, 1579-1591.	0.7	29
18	Should We Be Doing Cytoreductive Surgery with HIPEC for Signet Ring Cell Appendiceal Adenocarcinoma? A Study from the US HIPEC Collaborative. Journal of Gastrointestinal Surgery, 2020, 24, 155-164.	0.9	27

#	Article	IF	CITATIONS
19	Is There a Role for Endoscopic Therapy as a Definitive Treatment for Post-Laparoscopic Bile Duct Injuries?. Journal of the American College of Surgeons, 2010, 211, 495-502.	0.2	26
20	Mayo Clinic Consensus Recommendations for the Depth of Excision in Primary Cutaneous Melanoma. Mayo Clinic Proceedings, 2011, 86, 522-528.	1.4	26
21	Limitations of Lymph Node Ratio, Evidence-Based Benchmarks, and the Importance of a Thorough Lymph Node Dissection in Melanoma. Annals of Surgical Oncology, 2013, 20, 4370-4377.	0.7	26
22	Adjuvant GM-CSF Improves Survival in High-risk Stage IIIC Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 467-472.	0.6	26
23	The Prognostic Role of the Preoperative Absolute Lymphocyte Count and Absolute Monocyte Count in Patients With Resected Advanced Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 252-258.	0.6	26
24	Readmissions After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a US HIPEC Collaborative Study. Journal of Gastrointestinal Surgery, 2020, 24, 165-176.	0.9	26
25	Integrated cancer networks improve compliance with national guidelines and outcomes for resectable gastric cancer. Cancer, 2020, 126, 1283-1294.	2.0	26
26	Evidence of Th2 polarization of the sentinel lymph node (SLN) in melanoma. Oncolmmunology, 2015, 4, e1026504.	2.1	25
27	Mucinous appendiceal neoplasms: classification, imaging, and HIPEC. Abdominal Radiology, 2019, 44, 1686-1702.	1.0	25
28	Advancements and challenges in treating advanced gastric cancer in the West. World Journal of Gastrointestinal Oncology, 2019, 11, 652-664.	0.8	25
29	Tumor-infiltrating lymphocyte response in cutaneous melanoma in the elderly predicts clinical outcomes. Melanoma Research, 2013, 23, 132-137.	0.6	24
30	Intussusception in adults and the role of evolving computed tomography technology. American Journal of Surgery, 2015, 209, 580-583.	0.9	24
31	Impact of Neoadjuvant Chemotherapy on the Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Multi-Institutional Retrospective Review. Journal of Clinical Medicine, 2020, 9, 748.	1.0	22
32	Comparison of open and closed hyperthermic intraperitoneal chemotherapy: Results from the United States hyperthermic intraperitoneal chemotherapy collaborative. World Journal of Gastrointestinal Oncology, 2020, 12, 756-767.	0.8	21
33	Preservation of the deep muscular fascia and locoregional control in melanoma. Surgery, 2013, 153, 535-541.	1.0	20
34	A pilot study of chromosomal aberrations and epigenetic changes in peripheral blood samples to identify patients with melanoma. Melanoma Research, 2015, 25, 406-411.	0.6	20
35	Predictors of Anastomotic Failure After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Does Technique Matter?. Annals of Surgical Oncology, 2020, 27, 783-792.	0.7	20
36	In-transit melanoma: an individualized approach. Oncology, 2011, 25, 1340-8.	0.4	19

3

#	Article	IF	Citations
37	Regional lymphatic immunity in melanoma. Melanoma Research, 2012, 22, 9-18.	0.6	18
38	Natural History of Merkel Cell Carcinoma Following Locoregional Recurrence. Annals of Surgical Oncology, 2012, 19, 2556-2562.	0.7	17
39	Training High-Volume Melanoma Surgeons to Perform a Novel Minimally Invasive Inguinal Lymphadenectomy: Report of a Prospective Multi-Institutional Trial. Journal of the American College of Surgeons, 2016, 222, 253-260.	0.2	16
40	Primary Tumor Sidedness is Predictive of Survival in Colon Cancer Patients Treated with Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A US HIPEC Collaborative Study. Annals of Surgical Oncology, 2019, 26, 2234-2240.	0.7	16
41	Implications of Postoperative Complications for Survival After Cytoreductive Surgery and HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative. Annals of Surgical Oncology, 2020, 27, 4980-4995.	0.7	15
42	A multi-institutional analysis of Textbook Outcomes among patients undergoing cytoreductive surgery for peritoneal surface malignancies. Surgical Oncology, 2021, 37, 101492.	0.8	15
43	Optimal Surveillance Frequency After CRS/HIPEC for Appendiceal and Colorectal Neoplasms: A Multi-institutional Analysis of the US HIPEC Collaborative. Annals of Surgical Oncology, 2020, 27, 134-146.	0.7	14
44	What is the Optimal Preoperative Imaging Modality for Assessing Peritoneal Cancer Index? An Analysis From the United States HIPEC Collaborative. Clinical Colorectal Cancer, 2020, 19, e1-e7.	1.0	14
45	Intrathoracic Chemoperfusion Decreases Recurrences in Patients with Full-Thickness Diaphragm Involvement with Mucinous Appendiceal Adenocarcinoma. Annals of Surgical Oncology, 2016, 23, 2914-2919.	0.7	13
46	Preoperative Risk Score for Predicting Incomplete Cytoreduction: A 12-Institution Study from the US HIPEC Collaborative. Annals of Surgical Oncology, 2020, 27, 156-164.	0.7	13
47	Development and Validation of an Explainable Machine Learning Model for Major Complications After Cytoreductive Surgery. JAMA Network Open, 2022, 5, e2212930.	2.8	13
48	Radiation Therapy for Retroperitoneal Sarcomas: Influences of Histology, Grade, and Size. Sarcoma, 2018, 2018, 1-8.	0.7	12
49	Optimizing outcomes for patients with gastric cancer peritoneal carcinomatosis. World Journal of Gastrointestinal Oncology, 2018, 10, 282-289.	0.8	12
50	"Answers in hours†A prospective clinical study using nanopore sequencing for bile duct cultures. Surgery, 2022, 171, 693-702.	1.0	12
51	Management of regional lymph nodes in the elderly melanoma patient: Patient selection, accuracy and prognostic implications. European Journal of Surgical Oncology, 2015, 41, 157-164.	0.5	11
52	The Intersection of Age and Tumor Biology with Postoperative Outcomes in Patients After Cytoreductive Surgery and HIPEC. Annals of Surgical Oncology, 2020, 27, 4894-4907.	0.7	11
53	Repeat Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Is Not Associated with Prohibitive Complications: Results of a Multiinstitutional Retrospective Study. Annals of Surgical Oncology, 2020, 27, 4883-4891.	0.7	11
54	Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways. Journal of Surgical Oncology, 2020, 122, 980-985.	0.8	10

#	Article	IF	CITATIONS
55	Impact of Perioperative Blood Transfusions on Outcomes After Hyperthermic Intraperitoneal Chemotherapy: A Propensity-Matched Analysis. Annals of Surgical Oncology, 2021, 28, 4499-4507.	0.7	10
56	CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative. Annals of Surgical Oncology, 2020, 27, 4996-5004.	0.7	8
57	Emergent pancreatectomy for neoplastic disease: outcomes analysis of 534 ACS-NSQIP patients. BMC Surgery, 2020, 20, 169.	0.6	8
58	The dynamic human immune response to cancer: it might just be rocket science. Immunotherapy, 2011, 3, 1021-1024.	1.0	7
59	Patient Selection for Cytoreductive Surgery. Surgical Oncology Clinics of North America, 2018, 27, 443-462.	0.6	7
60	Robotic-assisted cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). Journal of Robotic Surgery, 2019, 13, 175-179.	1.0	7
61	Elevated brain natriuretic peptide (BNP) is an early marker for patients at risk for complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS + HIPEC). Journal of Surgical Oncology, 2018, 117, 685-691.	0.8	6
62	Association of Common Medications and the Risk of Early-Onset Gastric Cancer: A Population-Based Matched Study. Journal of Cancer Epidemiology, 2021, 2021, 1-6.	0.5	6
63	Pyogenic liver abscess secondary to Streptococcus anginosus in an adolescent. Journal of Pediatric Surgery, 2010, 45, e15-e17.	0.8	5
64	Predictors of Non-home Discharge after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Journal of Surgical Research, 2020, 255, 475-485.	0.8	5
65	The impact of HIPEC vs. EPIC for the treatment of mucinous appendiceal carcinoma: a study from the US HIPEC collaborative. International Journal of Hyperthermia, 2020, 37, 1182-1188.	1.1	5
66	Frozen section analysis of SLNs in trunk and extremity melanoma has a high false negative rate but can spare some patients a second operation. Journal of Surgical Oncology, 2016, 114, 879-883.	0.8	4
67	Preoperative opioid use is associated with increased length of stay after pancreaticoduodenectomy. Hpb, 2020, 22, 1074-1081.	0.1	4
68	A novel preoperative risk score to optimize patient selection for performing concomitant liver resection with cytoreductive surgery/HIPEC. Journal of Surgical Oncology, 2021, 123, 187-195.	0.8	4
69	The Utility of Preoperative Tumor Markers in Peritoneal Carcinomatosis from Primary Appendiceal Adenocarcinoma: an Analysis from the US HIPEC Collaborative. Journal of Gastrointestinal Surgery, 2021, 25, 2908-2919.	0.9	4
70	Surgical Management of Metastatic Gastrointestinal Stromal Tumors. Current Treatment Options in Oncology, 2021, 22, 37.	1.3	4
71	What is the Risk for Peritoneal Metastases and Survival Afterwards in T4 Colon Cancers?. Annals of Surgical Oncology, 2022, 29, 4224-4233.	0.7	4
72	Can cryptogenic multifocal ulcerous stenosing enteritis (CMUSE) be diagnosed in a patient with non-steroidal anti-inflammatory drug exposure?. BMJ Case Reports, 2021, 14, e238160.	0.2	3

#	Article	lF	CITATIONS
73	Finding the Balance: General Surgery Resident Versus Fellow Training and Exposure in Hepatobiliary and Pancreatic Surgery. Journal of Surgical Education, 2021, 78, 875-884.	1.2	3
74	Perception versus reality: A National Cohort Analysis of the surgeryâ€first approach for resectable pancreatic cancer. Cancer Medicine, 2021, 10, 5925-5935.	1.3	3
75	Prognostic Significance of Preoperative Tumor Markers in Pseudomyxoma Peritonei from Low-Grade Appendiceal Mucinous Neoplasm: a Study from the US HIPEC Collaborative. Journal of Gastrointestinal Surgery, 2022, 26, 414-424.	0.9	3
76	Intraoperative bile duct cultures in patients undergoing pancreatic head resection: Prospective comparison of bile duct swab versus bile duct aspiration. Surgery, 2021, 170, 1794-1798.	1.0	2
77	ASO Visual Abstract: What is the Risk for Peritoneal Metastases and Survival Afterwards in T4 Colon Cancers?. Annals of Surgical Oncology, 2022, , 1.	0.7	1
78	Adult Intussusception in the Last 25 Years of Modern Imaging: Is Surgery Still Indicated. Gastroenterology, 2011, 140, S-1011.	0.6	0
79	Sentinel Lymph Node Biopsy in Multicentric Breast Cancer: Five-Year Results in a Large Series from a Single Institution. Breast Diseases, 2012, 23, 174-176.	0.0	0
80	Is There Still a Role for Axillary Dissection in Breast Cancer Surgery?. Current Breast Cancer Reports, 2012, 4, 110-118.	0.5	0
81	Recurrence patterns following a negative sentinel lymph node biopsy (SLNB) for Merkel cell carcinoma (MCC). Journal of the American College of Surgeons, 2014, 219, e174.	0.2	0
82	Abstract 1266: Immune cell profile of the SLN has prognostic value in stage III melanoma , 2013, , .		0
83	Abstract A135: ConcurrentMCL1andJUNamplification in pseudomyxoma peritonei, 2013, , .		0
84	ASO Visual Abstract: Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer. Annals of Surgical Oncology, 2022, 29, 1594-1595.	0.7	0
85	Is CRS-HIPEC Still Indicated in Patients With Extraperitoneal Disease?. Journal of Surgical Research, 2022, 277, 269-278.	0.8	0
86	Can We Predict Surgical Futility/Cure in Gallbladder Cancer?. Annals of Surgical Oncology, 0, , .	0.7	0